Integrum AB Class B stock analysis
Integrum AB Class B (6Y1) Stock Price & Analysis
6Y1 Stock Chart & Stats
- Day’s Range
- EUR 0.69 - EUR 0.69
- 52-Week Range
- EUR 0.59 - EUR 1.03
- Previous Close
- EUR 0.69
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 21.73M
- Enterprise Value
- EUR 221.88M
- Total Cash (Recent Filing)
- EUR 15.01M
- Total Debt (Recent Filing)
- EUR 2.74M
- Price to Earnings (P/E)
- ―
- Beta
- 0.72
- Next Earnings
- Dec 03, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Specialized Osseointegration Technology
The company operates in a specialized medical-device niche centered on osseointegration, with implants, surgical solutions, and clinical support addressing mobility and quality-of-life needs. This focused platform can support durable relevance as clinical adoption and patient demand develop.
Meaningful Revenue Growth
Revenue growth indicates that Integrum has continued expanding commercial activity despite its current losses. Sustained top-line progress can improve operating leverage over time, strengthen the installed business base, and provide a foundation for eventual profitability if expenses become better aligned with sales.
Very Low Financial Leverage
Very low leverage gives Integrum greater financial flexibility and reduces solvency pressure compared with a highly indebted structure. Substantial equity relative to assets provides resilience while management works to improve operations, although the benefit depends on controlling ongoing losses and cash use.
Bears Say
Severe Current Profitability Weakness
Negative gross profit and deeply negative operating and net margins show that current revenue is not covering the company’s cost base. Unless margins recover, continued losses can constrain reinvestment, weaken returns on capital, and make growth increasingly dependent on external funding.
Persistent Operating Cash Burn
Materially negative operating and free cash flow indicate that the business is not currently self-funding its operations. Continued cash burn can increase funding dependence over the next several quarters and reduce the financial flexibility otherwise provided by the company’s low-debt balance sheet.
Unstable Earnings Profile
Large swings between profitability and sizeable losses make future earnings power difficult to rely on and indicate execution risk. This instability can delay the conversion of revenue growth into durable shareholder returns, particularly while return on equity remains strongly negative.
Integrum AB Class B News
6Y1 FAQ
What was Integrum AB Class B’s price range in the past 12 months?
What is Integrum AB Class B’s market cap?
When is Integrum AB Class B’s upcoming earnings report date?
How were Integrum AB Class B’s earnings last quarter?
Is Integrum AB Class B overvalued?
Does Integrum AB Class B pay dividends?
What is Integrum AB Class B’s EPS estimate?
How many shares outstanding does Integrum AB Class B have?
What happened to Integrum AB Class B’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Integrum AB Class B?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Integrum AB Class B
Integrum AB (publ) focuses on the research, development, and global sale of advanced bone-anchored prosthetic solutions. A core offering is the Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant system. This innovative bone-anchored prosthesis integrates directly with the patient's bone through osseointegration, thus circumventing the need for a conventional socket. A significant benefit of the OPRA system is its protective quality, helping to prevent bone fractures from accidental loads. Additionally, Integrum provides Neuromotus, a therapeutic technology designed to mitigate phantom limb pain following an amputation. These sophisticated implant systems are distributed worldwide to hospitals, clinics, and orthopedic professionals. The company was founded in 1962 and is based in Mölndal, Sweden.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Martin Hillsten
- Employees
- 33
- Website
- www.integrum.se
- Address
- Gemenskapens gata 9, Mölndal, VG, 431 53, SE
Integrum AB Class B (6Y1) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 1 | 0 | 11 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| SE:GETI.BGetinge | ||
| SE:SEZISenzime AB | ||
| SE:BACTI.BBactiguard Holding AB | ||
| SE:SECT.BSectra AB Class B | ||
| SE:OSSDOssDsign AB |





